GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (STU:L74) » Definitions » Operating Margin %

WuXi XDC Cayman (STU:L74) Operating Margin % : 22.30% (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. WuXi XDC Cayman's Operating Income for the six months ended in Dec. 2024 was €69.8 Mil. WuXi XDC Cayman's Revenue for the six months ended in Dec. 2024 was €313.1 Mil. Therefore, WuXi XDC Cayman's Operating Margin % for the quarter that ended in Dec. 2024 was 22.30%.

The historical rank and industry rank for WuXi XDC Cayman's Operating Margin % or its related term are showing as below:

STU:L74' s Operating Margin % Range Over the Past 10 Years
Min: 14.3   Med: 19.33   Max: 34.53
Current: 23.41


STU:L74's Operating Margin % is ranked better than
92.82% of 209 companies
in the Medical Diagnostics & Research industry
Industry Median: -4.08 vs STU:L74: 23.41

WuXi XDC Cayman's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

WuXi XDC Cayman's Operating Income for the six months ended in Dec. 2024 was €69.8 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 was €123.1 Mil.


WuXi XDC Cayman Operating Margin % Historical Data

The historical data trend for WuXi XDC Cayman's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman Operating Margin % Chart

WuXi XDC Cayman Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Operating Margin %
34.54 19.33 14.30 18.92 23.41

WuXi XDC Cayman Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Operating Margin % Get a 7-Day Free Trial 7.55 20.81 17.26 24.99 22.30

Competitive Comparison of WuXi XDC Cayman's Operating Margin %

For the Diagnostics & Research subindustry, WuXi XDC Cayman's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi XDC Cayman's Operating Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Operating Margin % distribution charts can be found below:

* The bar in red indicates where WuXi XDC Cayman's Operating Margin % falls into.


;
;

WuXi XDC Cayman Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

WuXi XDC Cayman's Operating Margin % for the fiscal year that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=124.418 / 531.538
=23.41 %

WuXi XDC Cayman's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=69.834 / 313.116
=22.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi XDC Cayman  (STU:L74) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


WuXi XDC Cayman Operating Margin % Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi XDC Cayman Business Description

Traded in Other Exchanges
Address
No. 11 Xinhui Ring Road, Xinwu, Jiangsu Province, Wuxi, CHN
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.

WuXi XDC Cayman Headlines

No Headlines